# Invivo Partners
Invivo Partners is a Spanish venture capital firm based in Barcelona that invests in early-stage life sciences companies at the intersection of advanced therapies, synthetic biology, and artificial intelligence; it is regulated as Invivo Partners, SGEIC, S.A.[1](https://www.gp-intel.com/gp/invivo-partners) The firm was co-founded by Dr. Luis Pareras and [Albert Ferrer](https://www.edgepedia.org/albert-ferrer).[2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) As of September 2025, its latest recorded event, it managed three funds with assets under management over €150 million, investments in 17 companies, and a partnership of Luis Pareras, Albert Ferrer, Laura Rodríguez, and Pep Martorell.[3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/)
| Fact | Detail |
|---|---|
| Registered name | Invivo Partners, SGEIC, S.A. (Barcelona, Spain) [1](https://www.gp-intel.com/gp/invivo-partners) |
| Founders | Dr. Luis Pareras and Albert Ferrer [2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) |
| Founding year | 2019 per The New Barcelona Post; c. 2012 per directory data and the firm's own "more than 12 years" statement in 2024 (disputed) [4](https://www.thenewbarcelonapost.com/invivo-lanza-un-nuevo-fondo-para-terapias-sanitarias-avanzadas-e-incluye-8-millones-del-icf/) • [1](https://www.gp-intel.com/gp/invivo-partners) |
| Funds | Invivo Ventures (2019 vintage, €60M, directory data); Invivo Ventures III (€100M target, 2024); Invivo Ventures AI (€100M, announced 2025) [1](https://www.gp-intel.com/gp/invivo-partners) • [2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) • [3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/) |
| Assets under management | Over €150 million across three funds (firm's statement, September 2025) [3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/) |
| Exits | Sanifit and Versantis trade sales; EsoBiotec trade sale (2025, directory-reported) [2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) • [1](https://www.gp-intel.com/gp/invivo-partners) |
| Status | Active; latest recorded event 23 September 2025 [3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/) |
## History and people
The firm's founding year is disputed. The New Barcelona Post reports that Albert Ferrer and Luis Pareras founded it in Barcelona in 2019.[4](https://www.thenewbarcelonapost.com/invivo-lanza-un-nuevo-fondo-para-terapias-sanitarias-avanzadas-e-incluye-8-millones-del-icf/) Directory data records a 2012 founding,[1](https://www.gp-intel.com/gp/invivo-partners) and Ferrer's own March 2024 statement that "it has been more than 12 years since we started this journey, with more than 15 portfolio companies invested in" is consistent with a start around 2012.[2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/)
Dr. Luis Pareras is the firm's Managing Partner and leads its investment thesis.[3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/) Laura Rodríguez was promoted from Principal to Partner in March 2024; she holds a PhD in [Biotechnology](https://www.edgepedia.org/biotechnology) with a background in oncology gene therapy research and worked in technology transfer at the Vall d'Hebron Hospital Research Institute.[2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) In September 2025, Pep Martorell joined as Partner, bringing expertise in technology transfer, AI, and entrepreneurship.[3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/)
## Strategy
Invivo Partners invests in early-stage life science companies working where advanced therapies, synthetic biology, and artificial intelligence meet.[2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) Pareras has framed the AI emphasis as a core bet: "our bold thesis is simple: in the near future, no deeptech company will survive without integrating AI."[3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/)
## Funds
**Invivo Ventures.** Directory data lists the firm's first named fund, Invivo Ventures, as a 2019-vintage vehicle of €60 million, harvesting with eight active positions and two realized exits.[1](https://www.gp-intel.com/gp/invivo-partners) The firm says its two earlier funds were backed by a majority of private investors alongside institutional investors including the European Investment Fund (EIF), Fond-ICO Global, the Catalan Finance Institute, the Valencia Institute of Finance, and the Barcelona City Council.[2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/)
**Invivo Ventures III.** In March 2024 the firm announced it was preparing Invivo Ventures III, a fund with a target volume of €100 million focused on advanced therapies, synthetic biology, and AI.[2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) The Institut Català de Finances (ICF), revalidating its earlier collaboration with the firm, invested €8 million, expandable to €10 million, in the fund, which the newspaper described as aimed at mobilizing €100 million for advanced therapies including cell therapy, synthetic biology, and AI.[4](https://www.thenewbarcelonapost.com/invivo-lanza-un-nuevo-fondo-para-terapias-sanitarias-avanzadas-e-incluye-8-millones-del-icf/)
**Invivo Ventures AI.** On 23 September 2025 the firm announced the planned launch of Invivo Ventures AI, a €100 million vertical fund dedicated to companies applying AI to science, announced alongside Martorell's arrival.[3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/)
## Portfolio and exits
The firm's earlier funds backed Catalan university spin-offs including Peptonyc (from the Institut d'Oncologia Vall d'Hebron, VHIO), Minoryx (University of Barcelona), Integra Therapeutics (Pompeu Fabra University) and Telomere Therapeutics (UAB/CNIO).[4](https://www.thenewbarcelonapost.com/invivo-lanza-un-nuevo-fondo-para-terapias-sanitarias-avanzadas-e-incluye-8-millones-del-icf/) Directory data adds portfolio entries [ARTHEx Biotech](https://www.edgepedia.org/arthex-biotech) (2020), [Corteria Pharmaceuticals](https://www.edgepedia.org/corteria-pharmaceuticals) (2021), Gyala (2020), OneChain Immunotherapeutics (2023), Pulmobiotics (2020), and Telomere Therapeutics (2020).[1](https://www.gp-intel.com/gp/invivo-partners)
The firm cites a track record of exits through the acquisitions of [Sanifit](https://www.edgepedia.org/sanifit) and Versantis in 2022, and later-stage rounds at portfolio companies such as Arthex's €42 million Series B in May 2023 and Corteria's €65 million Series A in September 2023.[2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) The Sanifit exit year differs across sources: the firm's release says 2022, while directory data records the Sanifit trade sale in 2021 and Versantis in 2022.[2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) • [1](https://www.gp-intel.com/gp/invivo-partners) Directory data also records an EsoBiotec trade sale in 2025 for the Belgian company entered in 2023, and 2025 portfolio entries Neumirna Therapeutics (Denmark) and Signadori Bio (France).[1](https://www.gp-intel.com/gp/invivo-partners)
## Recent developments
Since 2023 the firm has announced a succession of expansions: the €100 million Invivo Ventures III in March 2024, Laura Rodríguez's promotion to Partner the same month, the EsoBiotec exit (directory-reported, 2025), and on 23 September 2025 both the planned €100 million Invivo Ventures AI fund and the hire of Pep Martorell as Partner.[2](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) • [1](https://www.gp-intel.com/gp/invivo-partners) • [3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/) Its assets under management stood above €150 million at the September 2025 announcement, per the firm.[3](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/)
## References
1. [Invivo Partners. VC GP, Spain | GP Intel](https://www.gp-intel.com/gp/invivo-partners) (directory data, unverified)
2. [Invivo Partners is preparing to launch a €100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences](https://invivo.partners/2024/03/05/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences/) (Invivo Partners, 5 March 2024)
3. [Invivo Partners prepares the launch of a €100M fund at the intersection of AI and science and welcomes Pep Martorell as Partner](https://invivo.partners/2025/09/23/invivo-partners-prepares-the-launch-of-a-e100m-fund-at-the-intersection-of-ai-and-science-and-welcomes-pep-martorell-as-partner/) (Invivo Partners, 23 September 2025)
4. [Invivo lanza un nuevo fondo para terapias sanitarias avanzadas e incluye 8 millones del ICF](https://www.thenewbarcelonapost.com/invivo-lanza-un-nuevo-fondo-para-terapias-sanitarias-avanzadas-e-incluye-8-millones-del-icf/) (The New Barcelona Post)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license